Human papillomavirus (HPV) Recruitment Study for Men
To participate in this study, call 813-745-6996 or email mensresearch@moffitt.org for more information.
While most people associate Human papillomavirus (HPV) infections with cervical cancer, the virus can cause six types of cancers, including oropharyngeal cancer (a type of head and neck cancer occurring in the tonsils, soft palate, and base of tongue) which is now more common in the U.S. and disproportionately affects men.
Most sexually active men will get an HPV infection at some time in their life. Most of the HPV infection will clear on their own. When the virus persists, it can cause abnormal changes in the cells which can lead to cancer. This highly prevalent virus is estimated to cause over 14000 HPV-related cancers in men annually in the U.S.
What is the HPV recruitment study for men?
Moffitt Cancer Center has been working for more than a decade to better understand HPV infections, especially in men. Researchers are testing a study vaccine to evaluate how the body handles the vaccine. This is a phase 3 trial among unvaccinated men to investigate the safety and effectiveness of the HPV vaccine in preventing persistent oral HPV infection, a precursor to oropharyngeal cancer. Currently, we're enrolling male participants between 20 to 45 years of age for a vaccine study.
Who can participate?
- Healthy men who are 20 to 45 years of age
- Men who have had at least one sexual partner during his life
- Those who have not already received an HPV vaccine
- Men who have no history of an HPV-related anal lesion or HPV-related head and neck cancer
If you're interested in participating in this study, call 813-745-6996 or email mensresearch@moffitt.org for more information.